Aspen Pharmacare Holdings, a leading global pharmaceutical company, has concluded an agreement to divest of its global Nutritional Business to the Lactalis Group, a leading multinational dairy corporation for £659m. Aspen’s disposal of the Nutritionals Business will allow the Aspen business units in Asia Pacific, Latin America and Sub-Saharan Africa to dedicate all of their time and attention to their core pharmaceutical businesses. This heightened focus is expected to drive increased business efficiency and performance. "The disposal is in line with our strategic intention to focus our attention on our core pharmaceutical business which includes the Anaesthetics, Thrombosis and High Potency & Cytotoxic portfolios. The heightened focus is expected to drive increased business efficiency and performance.” Stephen Saad, Aspen Group Chief Executive.